NCT03932786 Studying Health Outcomes After Treatment in Patients With Retinoblastoma
| NCT ID | NCT03932786 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Condition | Retinoblastoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 900 participants |
| Start Date | 2019-01-24 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 900 participants in total. It began in 2019-01-24 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma
Eligibility Criteria
* Unilateral or bilateral intraocular retinoblastoma * Diagnosis between the ages of 0 - 17.99 years * Diagnosis on or after January 1, 2008 * No exclusions based on primary or secondary treatment modalities * Retrospective group patients must be ≥ 6 months post end of treatment at study entry * For those already at this timepoint, they are now eligible * For those in treatment, or otherwise not yet at this timepoint, they are eligible once at they are ≥ 6 months post end of treatment * Prospective group patients must not have begun treatment * Patients with diminished capacity will not be enrolled. * Language: Patients must be able to communicate in English, French, or Spanish * Sibling Cohort: One sibling, not affected by retinoblastoma will be enrolled, preference for the sibling closest in age to the RB patient. * Regulatory Requirements: All patients and/or their parents or legal guardians must sign a written informed consent. All institutional, FDA, and NCI requirements for human studies must be met.
Contact & Investigator
Debra Friedman, MD
PRINCIPAL INVESTIGATOR
Vanderbilt Medical Center
Frequently Asked Questions
Who can join the NCT03932786 clinical trial?
This trial is open to participants of all sexes, studying Retinoblastoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03932786 currently recruiting?
Yes, NCT03932786 is actively recruiting participants. Contact the research team at cip@vanderbilt.edu for enrollment information.
Where is the NCT03932786 trial being conducted?
This trial is being conducted at Chicago, United States, Chicago, United States, Minneapolis, United States, St Louis, United States and 7 additional locations.
Who is sponsoring the NCT03932786 clinical trial?
NCT03932786 is sponsored by Vanderbilt-Ingram Cancer Center. The principal investigator is Debra Friedman, MD at Vanderbilt Medical Center. The trial plans to enroll 900 participants.